• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Equivalence of SYN008 versus omalizumab in patients with refractory chronic spontaneous urticaria: A multicenter, randomized, double-blind, parallel-group, active-controlled phase III study.

作者信息

Li Jingyi, Liang Yunsheng, Feng Wenli, Deng Liehua, Fang Hong, Ji Chao, Lin Youkun, Zhang Furen, Xia Rushan, Zhang Chunlei, Guo Shuping, Lin Mao, Li Yanling, Zhang Shoumin, Kang Xiaojing, Chen Liuqing, Song Zhiqiang, Yao Xu, Li Chengxin, Han Xiuping, Guo Guoxiang, Guo Qing, Duan Xinsuo, Li Jie, Su Juan, Li Shanshan, Sun Qing, Tao Juan, Ding Yangfeng, Deng Danqi, Li Fuqiu, Suo Haiyun, Wu Shunquan, Qiu Jingbo, Luo Hongmei, Li Linfeng, Li Ruoyu

机构信息

Department of Dermatology, West China Hospital Sichuan University, Chengdu, Sichuan 610041, China.

Dermatology Hospital of Southern Medical University, Guangzhou, Guangdong 510091, China.

出版信息

Chin Med J (Engl). 2025 Aug 20;138(16):2040-2042. doi: 10.1097/CM9.0000000000003593. Epub 2025 Jun 6.

DOI:10.1097/CM9.0000000000003593
PMID:40474341
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12369717/
Abstract
摘要

相似文献

1
Equivalence of SYN008 versus omalizumab in patients with refractory chronic spontaneous urticaria: A multicenter, randomized, double-blind, parallel-group, active-controlled phase III study.SYN008与奥马珠单抗治疗难治性慢性自发性荨麻疹患者的等效性：一项多中心、随机、双盲、平行组、活性药物对照的III期研究。
Chin Med J (Engl). 2025 Aug 20;138(16):2040-2042. doi: 10.1097/CM9.0000000000003593. Epub 2025 Jun 6.
2
CT-P39 Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double-Blind, Randomized, Active-Controlled, Phase 3 Study.CT-P39与对照奥马珠单抗治疗慢性自发性荨麻疹的比较：一项双盲、随机、活性对照3期研究的结果
Allergy. 2025 Jan 9. doi: 10.1111/all.16446.
3
Multinational Drug Survival Study of Omalizumab in Patients With Chronic Urticaria and Potential Predictors for Discontinuation.奥马珠单抗治疗慢性荨麻疹的多国药物生存研究及停药的潜在预测因素
JAMA Dermatol. 2024 Sep 1;160(9):927-935. doi: 10.1001/jamadermatol.2024.2056.
4
Rilzabrutinib in Antihistamine-Refractory Chronic Spontaneous Urticaria: The RILECSU Phase 2 Randomized Clinical Trial.利扎布替尼治疗抗组胺药难治性慢性自发性荨麻疹：RILECSU 2期随机临床试验
JAMA Dermatol. 2025 Apr 23. doi: 10.1001/jamadermatol.2025.0733.
5
Comparison between chronic spontaneous urticaria and chronic induced urticaria on the efficacy of omalizumab treatment: A systematic review and meta-analysis.慢性自发性荨麻疹与慢性诱导性荨麻疹在奥马珠单抗治疗效果方面的比较：系统评价和荟萃分析。
Dermatol Ther. 2022 Dec;35(12):e15928. doi: 10.1111/dth.15928. Epub 2022 Oct 26.
6
The Efficacy of Different Dosing Regimens of Omalizumab in Children and Adolescents with Chronic Spontaneous Urticaria Based on Real-Life Data.基于真实生活数据的奥马珠单抗不同给药方案对儿童和青少年慢性自发性荨麻疹的疗效
Int Arch Allergy Immunol. 2025 Jun 4:1-10. doi: 10.1159/000545336.
7
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.利格司亭在成人和青少年慢性自发性荨麻疹患者中的疗效和安全性：两项 3 期随机对照研究结果。
Lancet. 2024 Jan 13;403(10422):147-159. doi: 10.1016/S0140-6736(23)01684-7. Epub 2023 Nov 23.
8
Impact of Pharmacological Treatments for Chronic Spontaneous Urticaria with an Inadequate Response to H1-Antihistamines on Health-Related Quality of Life: A Systematic Review and Network Meta-Analysis.抗组胺药治疗慢性自发性荨麻疹疗效不佳患者的药物治疗对健康相关生活质量的影响：系统评价和网络荟萃分析。
J Allergy Clin Immunol Pract. 2022 Jan;10(1):297-308. doi: 10.1016/j.jaip.2021.10.022. Epub 2021 Oct 22.
9
Omalizumab in pediatric chronic spontaneous urticaria: A systematic review and meta-analysis of efficacy and safety.奥马珠单抗治疗儿童慢性自发性荨麻疹：疗效与安全性的系统评价和荟萃分析
Pediatr Allergy Immunol. 2025 Jun;36(6):e70132. doi: 10.1111/pai.70132.
10
Evaluation of Pharmacologic Treatments for H1 Antihistamine-Refractory Chronic Spontaneous Urticaria: A Systematic Review and Network Meta-analysis.评价 H1 抗组胺药难治性慢性自发性荨麻疹的药物治疗：系统评价和网络荟萃分析。
JAMA Dermatol. 2021 Nov 1;157(11):1316-1327. doi: 10.1001/jamadermatol.2021.3237.

本文引用的文献

1
Urticaria.荨麻疹。
Nat Rev Dis Primers. 2022 Sep 15;8(1):61. doi: 10.1038/s41572-022-00389-z.
2
Epidemiology of urticaria in China: a population-based study.中国荨麻疹的流行病学：一项基于人群的研究。
Chin Med J (Engl). 2022 Jun 5;135(11):1369-1375. doi: 10.1097/CM9.0000000000002172.
3
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria.国际 EAACI/GA²LEN/EuroGuiDerm/APAAACI 荨麻疹定义、分类、诊断和管理指南。
Allergy. 2022 Mar;77(3):734-766. doi: 10.1111/all.15090. Epub 2021 Oct 20.
4
Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials.奥马珠单抗治疗慢性自发性荨麻疹：一项随机临床试验的荟萃分析。
J Allergy Clin Immunol. 2016 Jun;137(6):1742-1750.e4. doi: 10.1016/j.jaci.2015.12.1342. Epub 2016 Mar 31.